3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
32
Breast Neoplasms
25
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Multiple Myeloma
13
Neoplasms
12
Leukemia, Myeloid, Acute
12
Ovarian Neoplasms
10
Neoplasm Metastasis
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Colorectal Neoplasms
8
Melanoma
7
Lymphoma, Non-Hodgkin
7
Leukemia
7
Stomach Neoplasms
6
Recurrence
6
Fallopian Tube Neoplasms
6
Carcinoma, Hepatocellular
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma
5
Adenocarcinoma
5
Purpura, Thrombocytopenic, Idiopathic
4
Myelodysplastic Syndromes
4
Lymphoma, Follicular
4
Liver Neoplasms
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Interventions
olaparib
1
cc-486
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
Pathologic Complete Response
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA